Peptide reported today that they sold off part of the drug business to Medivir of Switzerland for 6 million STG. I assume this was the protease inhibitor business. Given their portfolio of vaccines for rare diseases that affect millions of people worldwide, no wonder Deutches Bank upgraded the stock with a target price of 185p from its current price of 90p The upgrade was several weeks ago, and I was wondering was it for this new announcement? Peptide Therapeutics Group is based in Cambridge, England and is in partnership with Medeva of Switzerland, Aventis Pasteur, Pfizer Eli Lily, Novartis, Peptimmune, the Research Council and the University of Dundee. They are working on vaccines such as: Arilvax Yellow Fever Vaccine, Oral Typhoid, H.Pylori, C. difficile, Veterinary Allergy vaccine, Oral ETEC, Japanese Encephalitis, Oral H. Pylori, Tick-born encephalitis, Hepatitis C, Menegitis B, the West Nile Encephalitis that hit New York City in 1999 and Dengue Fever Vaccine. Dengue Fever infects 100,000,000 people every year and kills 24,000 children each year, mostly in central and South America where people can afford a vaccine. It is PTE on the LSE
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra